Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21246171 | 0.86 | RECQL (0.53) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL29884167 | 0.86 | RECQL (0.53) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL1933893 | 0.80 | HDAC3 (0.51) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL14715294 | 0.79 | BAZ2B (0.43) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL23022741 | 0.79 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL3003567 | 0.79 | NPSR1 (0.50) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL29602711 | 0.79 | NPSR1 (0.50) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL3003564 | 0.79 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL30772894 | 0.76 | ALDH1A1 (0.48) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 | |
| SCHEMBL26122852 | 0.76 | ALDH1A1 (0.48) | HDAC3HDAC1HDAC2HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | HDAC3 364/4885HDAC1 289/4885HDAC2 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.